University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.

Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.

Russell Szmulewitz, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the optimal use of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

Thomas F. Gajewski, MD, PhD, discusses how the field of immune checkpoints is expanding beyond PD-1 and CTLA-4.

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

Victoria M. Villaflor, MD, medical oncologist, associate professor of medicine, The University of Chicago Medicine, discusses findings from a response-adapted volume de-escalation of radiotherapy using induction chemotherapy in locally advanced head and neck squamous cell cancer.

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the efficacy of pembrolizumab and atezolizumab for the treatment of patients with metastatic triple-negative breast cancer.

OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.

The signing of the Medical Access and CHIP Reauthorization Act of 2015 ends the yearly nightmare of congressional budget wrangling associated with the Sustainable Growth Rate formula.

With the flourish of a pen, President Obama put an end to a yearly nightmare of congressional budget wrangling when he signed the Medical Access and CHIP Reauthorization Act of 2015, otherwise known as the Sustainable Growth Rate formula repeal.

Jason J. Luke, MD, FACP, discusses the stark change in funding priorities by the United States for biomedical research, and the consequences of that.

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

With the proliferation of agents for cancer over the past few years, including both targeted and immunotherapies, the number of clinical questions surround- ing optimal sequencing and combinations approaches infinity.

OncLive® welcomes the University of Chicago Medicine Comprehensive Cancer Center as a partner in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program.

Katharine Yao, MD, director, breast surgical program, NorthShore University HealthSystem, Evanston, Illinois, clinical associate professor, surgery, Pritzker School of Medicine, University of Chicago, discusses a prospective study that analyzed the sources of information regarding decisions on contralateral prophylactic mastectomy.

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the current and future state of multiple myeloma treatmen

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Everett E. Vokes, MD, was recognized by the "Giants of Cancer Care" awards program for his groundbreaking research into head and neck cancers.

Everett E. Vokes, MD, Giant of Cancer Care in the Head and Neck Cancer Category, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses HPV-related head and neck cancer

Everett E. Vokes, MD, Giant of Cancer Care in Head and Neck from University of Chicago Medicine and Biological Sciences, discusses multimodality therapy for lung cancer.

Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses sequestration and the effect on the FDA.

New research suggests that there may be five distinct subgroups of head and neck cancer in which specific genetic profiles may be utilized to guide treatment decisions in patients.